Victor J. Marder
#115,668
Most Influential Person Now
Victor J. Marder's AcademicInfluence.com Rankings
Victor J. Marderphilosophy Degrees
Philosophy
#5011
World Rank
#7714
Historical Rank
Logic
#2362
World Rank
#3341
Historical Rank
Victor J. Marderbiology Degrees
Biology
#6680
World Rank
#9448
Historical Rank
Cell Biology
#226
World Rank
#234
Historical Rank
Download Badge
Philosophy Biology
Victor J. Marder's Degrees
- Doctorate Medicine Stanford University
Why Is Victor J. Marder Influential?
(Suggest an Edit or Addition)Victor J. Marder's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells (1982) (707)
- A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. (1994) (498)
- Inducible secretion of large, biologically potent von Willebrand factor multimers (1986) (456)
- Thrombolytic Therapy: Current Status (1988) (447)
- CT and MRI Early Vessel Signs Reflect Clot Composition in Acute Stroke (2011) (420)
- Air pollution and markers of inflammation and coagulation in patients with coronary heart disease. (2006) (390)
- High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. (1969) (385)
- SIMILARITIES BETWEEN KNOWN ANTIPLATELET ANTIBODIES AND THE FACTOR RESPONSIBLE FOR THROMBOCYTOPENIA IN IDIOPATHIC PURPURA. PHYSIOLOGIC, SEROLOGIC AND ISOTOPIC STUDIES (1965) (325)
- Analysis of Thrombi Retrieved From Cerebral Arteries of Patients With Acute Ischemic Stroke (2006) (324)
- Thrombogenic factors and recurrent coronary events. (1999) (301)
- Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization (1984) (290)
- Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. (1977) (276)
- Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. (2005) (273)
- Biosynthesis of von Willebrand protein by human megakaryocytes. (1985) (262)
- NF-kappa B-dependent inhibition of apoptosis is essential for host cellsurvival during Rickettsia rickettsii infection. (1998) (245)
- Enhancement of fibrinolysis in vitro by ultrasound. (1992) (234)
- Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. (1983) (230)
- Overview of hemostasis (2002) (205)
- Thrombin activity of fibrin thrombi and soluble plasmic derivatives. (1983) (193)
- Analysis of Thrombi Retrieved from Cerebral Arteries of Patients with Acute Ischemic Stroke. (2005) (191)
- Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. (1980) (188)
- The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. (1979) (176)
- ISOIMMUNE NEONATAL THROMBOCYTOPENIC PURPURA. CLINICAL AND THERAPEUTIC CONSIDERATIONS. (1964) (176)
- Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor (1986) (169)
- Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. (1992) (164)
- Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. (2001) (151)
- Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. (1983) (144)
- High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. (1969) (141)
- VON WILLEBRAND FACTOR RELEASED FROM WEIBEL-PALADE BODIES BINDS MORE AVIDLY TO EXTRACELLULAR MATRIX THAN THAT SECRETED CONSTITUTIVELY (1987) (138)
- The size of human factor VIII heterodimers and the effects produced by thrombin. (1986) (138)
- Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. (1980) (135)
- PLATELET AND LEUKOCYTE ISOANTIGENS AND THEIR ANTIBODIES: SEROLOGIC PHYSIOLOGIC AND CLINICAL STUDIES. (1964) (130)
- Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells (1989) (118)
- DIVERGENT PATES OF VON WILLEBRAND FACTOR AND ITS PROPOLYPEPTIDE (VON WILLEBRAND ANTIGEN II) AFTER SECRETION FROM ENDOTHELIAL CELLS (1987) (117)
- Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. (1988) (112)
- Ultrasound enhancement of thrombolysis and reperfusion in vitro. (1993) (108)
- Topology and order of formation of interchain disulfide bonds in von Willebrand factor. (1987) (98)
- INCREASED PLASMA CONCENTRATION OF CROSSLINKED FIBRIN POLYMERS IN ACUTE MYOCARDIAL INFARCTION (1987) (92)
- β-globin gene transfer to human bone marrow for sickle cell disease. (2013) (89)
- Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. (1986) (89)
- Plasmin Induces Local Thrombolysis without Causing Hemorrhage: A Comparison with Tissue Plasminogen Activator in the Rabbit (2001) (88)
- Prevention of Deep-Vein Thrombosis after Total Hip Arthroplasty. Comparison of Warfarin and Dalteparin* (1997) (87)
- Detection of serum fibrinogen and fibrin degradation products. Comparison of six technics using purified products and application in clinical studies. (1971) (85)
- Acquired "storage pool disease" of platelets associated with circulating antiplatelet antibodies. (1974) (85)
- Physiologic regulation and pathologic disorders of fibrinolysis. (1987) (85)
- Von Willebrand protein binds to extracellular matrices independently of collagen. (1984) (85)
- CLINICAL ASPECTS OF CONGENITAL FACTOR VII DEFICIENCY. (1964) (84)
- A molecular model of plasmic degradation of crosslinked fibrin. (1982) (83)
- Flow through clots determines the rate and pattern of fibrinolysis. (1994) (82)
- Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. (1980) (81)
- Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. (2012) (80)
- Polarized secretion of fibrinogen by lung epithelial cells. (1997) (79)
- Structure of plasmic degradation products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis. (1974) (77)
- Primary fibrinolysis during supraceliac aortic clamping. (1997) (77)
- Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy. (1994) (75)
- Short-term effects of air pollution: a panel study of blood markers in patients with chronic pulmonary disease (2009) (74)
- MulticenterPatency Trial ofIntravenous Anistreplase ComparedWith Streptokinase in AcuteMyocardial Infarction (1991) (73)
- Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential (2010) (73)
- Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. (1980) (72)
- Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. (2004) (72)
- Rickettsia rickettsii infection of cultured human endothelial cells induces NF-kappaB activation (1997) (72)
- RAPID FORMATION OF LARGE MOLECULAR WEIGHT O-P0LYMERS IN CROSSLINKED FIBRIN INDUCED BY HIGH FACTOR XIII CONCENTRATIONS: ROLE OF PLATELET FACTOR XIII. (1987) (70)
- Embolic complications of calf thrombosis following total hip arthroplasty. (1993) (69)
- Large-Scale Trials of Thrombolytic Therapy for Acute Myocardial Infarction: GISSI-2, ISIS-3, and GUSTO-1 (1993) (68)
- Effects of enzymatic degradation on the subunit composition and biologic properties of human factor VIII. (1978) (67)
- Prevention of venous thrombosis after total hip arthroplasty. Antithrombin III and low-dose heparin compared with dextran 40. (1989) (66)
- Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. (1985) (65)
- Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. (2003) (65)
- Interleukin-1 alpha production during Rickettsia rickettsii infection of cultured endothelial cells: potential role in autocrine cell stimulation (1996) (65)
- Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction. (1991) (64)
- Photosensitized release of von Willebrand factor from cultured human endothelial cells. (1991) (63)
- Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: A systematic review (2005) (62)
- Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. (2002) (62)
- High molecular weight derivatives of human fibrinogen produced by plasmin. 3. Their NH2-terminal amino acids and comparison with the "NH2-terminal disulfide knot". (1972) (59)
- Controlled trial of low-dose heparin and sulfinpyrazone to prevent venous thromboembolism after operation on the hip. (1978) (57)
- Rickettsia rickettsii infection of cultured endothelial cells induces release of large von Willebrand factor multimers from Weibel-Palade bodies. (1991) (56)
- Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain-variant polypeptides. (1989) (56)
- E-selectin-dependent neutrophil adhesion to Rickettsia rickettsii-infected endothelial cells. (1993) (55)
- Cocaine and Buerger disease: is there a pathogenetic association? (2000) (55)
- The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage. (1967) (54)
- Comparison of Two Warfarin Regimens in the Prevention of Venous Thrombosis following Total Knee Replacement (1996) (54)
- Recombinant streptokinase: opportunity for an improved agent. (1993) (53)
- Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides. (1984) (53)
- Rickettsia rickettsii infection of cultured human endothelial cells induces tissue factor expression. (1994) (52)
- Thrombolysis With Plasmin: Implications for Stroke Treatment (2010) (52)
- LOWER RISK OF THROMBOEMBOLIC DISEASE AFTER TOTAL HIP REPLACEMENT WITH NON-CEMENTED THAN WITH CEMENTED PROSTHESES (1986) (51)
- Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury. (1994) (51)
- Anti‐PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non‐drug risk factors and evidence for a stoichiometry‐based model of immunization (2010) (51)
- Proteasome-Independent Activation of Nuclear Factor κB in Cytoplasmic Extracts from Human Endothelial Cells byRickettsia rickettsii (1998) (50)
- Transcriptional Regulation of Endothelial Cell Tissue Factor Expression during Rickettsia rickettsiiInfection: Involvement of the Transcription Factor NF-κB (1998) (49)
- Enzymatic Degradation of the Factor VIII-Von Willebrand Protein:A Unique Tryptic Fragment with Ristocetin Co-Factor Activity (1980) (49)
- Prevention of venous thrombosis after total knee arthroplasty. Comparison of antithrombin III and low-dose heparin with dextran. (1990) (49)
- Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments. (1993) (49)
- Purification and characterization of a highly purified human factor VIII consisting of a single type of polypeptide chain. (1982) (49)
- Irradiation induces release of von Willebrand protein from endothelial cells in culture (1984) (48)
- Structural Studies On The Functional Heterogeneity Of Von Willebrand Protein Polymers (1981) (47)
- Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique. (1985) (46)
- Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. (1992) (45)
- Standard Nomenclature for Factor VIII and von Willebrand Factor: A Recommendation by the International Committee on Thrombosis and Haemostasis (1985) (45)
- Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty (2003) (44)
- Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. (1992) (44)
- Towards safer thrombolytic therapy. (2002) (43)
- Comparative Effects of Fibrinogen Degradation Fragments D and E on Coagulation (1972) (42)
- Irradiation induces release of von Willebrand protein from endothelial cells in culture. (1984) (42)
- DDAVP Reduces Bleeding during Continued Hirudin Administration in the Rabbit (1996) (42)
- PLASMIN DEGRADATION OF CROSS‐LINKED FIBRIN * (1983) (42)
- Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty. (1988) (42)
- Defect in the gamma polypeptide chain of a congenital abnormal fibrinogen (Paris I) (1974) (42)
- Formation of highly ordered polymers from fibrinogen and fibrin degradation products. (1970) (42)
- Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. (1986) (41)
- Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction ∗ (2000) (40)
- Heparin-binding domain of fibrin mediates its binding to endothelial cells. (1996) (40)
- The Relationship of Platelet Coagulant Activities to Venous Thrombosis following Hip Surgery * (1976) (39)
- Fibrinolytic therapy for venous thrombosis. (1991) (39)
- Major surgery in classic hemophilia using fraction I: Experience in twelve operations and review of the literature (1966) (39)
- Demonstration of in situ fibrin degradation in pathologic thrombi. (1984) (39)
- Rituximab for treatment of inhibitors in haemophilia A (2014) (39)
- Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. (1990) (38)
- Antigenic markers on fragment DD, a unique plasmic derivative of human crosslinked fibrin (1979) (36)
- Comparison of the physicochemical properties of fragment D derivatives of fibrinogen and fragment D-D of cross-linked fibrin. (1976) (36)
- Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin (2003) (36)
- Complement-fixing isoantibodies against antigens common to platelets and leukocytes. (1962) (36)
- Middle Cerebral Artery Occlusion in the Rabbit Using Selective Angiography: Application for Assessment of Thrombolysis (2008) (36)
- Data for Defining Fibrinogen and Its Plasmic Degradation Products (1975) (36)
- Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments. (1990) (36)
- Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. (1995) (34)
- Quantitative assessment of thrombus burden predicts the outcome of treatment for venous thrombosis: a systematic review. (2005) (34)
- Biosynthesis of von Willebrand Protein by Human Endothelial Cells" Processing and Their Intracellular Localization Steps (1984) (34)
- Successful thrombolytic therapy in two patients with renal vein thrombosis. (1984) (33)
- Degradation of cross-linked fibrin by human leukocyte proteases. (1986) (33)
- Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. (1986) (33)
- Ancrod and Fibrin Formation: Perspectives on Mechanisms of Action (2011) (32)
- Thrombolytic therapy: current status (1). (1988) (32)
- A Response to Holding GUSTO Up to the Light (1994) (32)
- Comparison of Native Prothrombin Antigen With the Prothrombin Time for Monitoring Oral Anticoagulant Prophylaxis (1993) (32)
- Plasma and Platelet Fibrinogen Differ in γ Chain Content (1984) (32)
- Rapid Formation of Large Molecular Weight a-Polymers in Cross-Linked Fibrin Induced by High Factor XIII Concentrations (1987) (32)
- Magnetic resonance imaging of blood and clots in vitro. (1990) (32)
- Current issues concerning thrombolytic therapy for acute myocardial infarction. (1995) (31)
- A first‐in‐human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion (2008) (31)
- Heparin-Binding Domain of Fibrin Mediates Its Binding to Endothelial Cells (1996) (31)
- On The Conversion Of High Molecular Weight Urokinase To The Low Molecular Weight Form (1981) (31)
- Detection of circulating crosslinked fibrin derivatives by a heat extraction-SDS gradient gel electrophoretic technique. (1979) (30)
- Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. (1987) (30)
- Angioedema during therapy with recombinant tissue plasminogen activator. (1991) (30)
- Developmental expression of mRNAs encoding platelet proteins in rat megakaryocytes. (1991) (30)
- Historical perspective and future direction of thrombolysis research: the re‐discovery of plasmin (2011) (29)
- Identification and purification of fibrinogen degradation products produced by plasmin: considerations on the structure of fibrinogen. (2009) (29)
- A Quantitative Evaluation of the Inhibition of Platelet Aggregation by Low Molecular Weight Degradation Products of Fibrinogen (1973) (29)
- Thrombolytic therapy for acute transmural myocardial infarction. Intracoronary versus intravenous. (1984) (29)
- The Purification of Fibrinogen Degradation Products by Pevikon Block Electrophoresis (1969) (29)
- Oral delivery of heparin: SNAC and related formulations. (2004) (29)
- Degradation of Bovine Factor VIII by Plasmin and Trypsin (1974) (28)
- Inhibition of disulfide bonding of von Willebrand protein by monensin results in small, functionally defective multimers (1985) (27)
- Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. (1983) (27)
- Degradation Products of Fibrinogen and Crosslinked Fibrin—Projected Clinical Applications (1974) (27)
- Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. (1992) (27)
- Hematologic neoplasia and the central nervous system (1999) (27)
- Increased Level of von Willebrand Factor Is Significantly and Independently Associated with Diabetes in Postinfarction Patients (2001) (26)
- Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. (1978) (26)
- Antigenic markers on fragment DD, a unique plasmic derivative of human crosslinked fibrin. (1979) (26)
- Concepts of clot lysis. (1986) (26)
- Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences. (1990) (26)
- Thrombolytic therapy for deep vein thrombosis: potential application of plasmin. (2009) (25)
- Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction (2007) (25)
- The C-terminal sequences of the gamma 57.5 chain of human fibrinogen constitute a plasmin sensitive epitope that is exposed in crosslinked fibrin. (1989) (25)
- Use of Thrombolytic Therapy for Acute Myocardial Infarction: Effects of Gender and Age on Treatment Rates (2002) (25)
- Thrombolytic therapy: 2001. (2001) (25)
- Relation of plasma D-dimer concentrations to coronary artery reperfusion before and after thrombolytic treatment in patients with acute myocardial infarction. (1989) (25)
- Mistaken guidelines for thrombolytic therapy of acute myocardial infarction in the elderly. (1991) (25)
- Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery (2012) (25)
- Guidelines for thrombolytic therapy of deep-vein thrombosis. (1979) (25)
- Thrombotic thrombocytopenic purpura: Recovery after splenectomy associated with persistence of abnormally large von willebrand factor multimers (2006) (24)
- Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis? (2004) (24)
- Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator. (2008) (24)
- Effects of ionic and nonionic radiographic contrast agents on endothelial cells in vitro. (1992) (23)
- Oral SNAC-heparin vs. enoxaparin for preventing venous thromboembolism following total hip replacement. (2002) (23)
- Same day outpatient transjugular liver biopsies in haemophilia (2004) (22)
- Effect of smoking on lipid and thrombogenic factors two months after acute myocardial infarction. (2000) (22)
- b-globin gene transfer to human bone marrow for sickle cell disease (2018) (22)
- Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders. (1992) (22)
- An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. (1992) (22)
- Phospholipid-bound Tissue Factor Modulates both Thrombin Generation and APC-mediated Factor Va Inactivation (1999) (22)
- Effects of fibrinogen degradation products on platelets and coagulation. (1966) (21)
- Safety of catheter‐delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results (2012) (21)
- Thrombolysis of acute or subacute nonembolic arterial thrombosis. (1977) (21)
- Electrophoresis of hemoglobin on agar gels; frequency of hemoglobin D in a Negro population. (1959) (21)
- Reactivity of Soluble Fibrin Assays with Plasmic Degradation Products of Fibrin and in Patients Receiving Fibrinolytic Therapy (1999) (21)
- Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients. (2003) (21)
- Relationship between electrocardiographic and biochemical variables in coronary artery disease. (2007) (21)
- Prophylaxis of venous thrombosis following total hip and total knee replacement using antithrombin III and heparin. (1991) (20)
- Orally active heparin and low–molecular-weight heparin (2001) (20)
- Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators. (2000) (20)
- Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease (2003) (19)
- Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. (2003) (19)
- Antithrombin III prophylaxis of venous thromboembolic disease after total hip or total knee replacement. (1989) (19)
- Plasminogen Depletion during Streptokinase Treatment or Two-Chain Urokinase Incubation Correlates with Decreased Clot Lysability Ex Vivo and In Vitro (1993) (19)
- Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model (2011) (19)
- Acute Myocardial Infarction Study of Adenosine (AMISTAD II) (2002) (18)
- Reaction of plasmic degradation products of fibrinogen in the radioimmunoassay of human fibrinopeptide A. (1975) (18)
- Increased Expression of Plasminogen Activator Inhibitor-1 in R.rickettssi-infected Endothelial Cells (1996) (18)
- Purification of three gamma-chains with different molecular weights from normal human plasma fibrinogen. (1984) (18)
- Acquired thrombophilic syndromes. (2001) (18)
- Modification of high molecular weight plasmic degradation products of human crosslinked fibrin. (1979) (17)
- Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers. (1989) (17)
- A Soluble Fibrin Standard: Comparable Dose-response with Immunologic and Functional Assays (1999) (16)
- Plasminogen acceleration of urokinase thrombolysis. (1994) (16)
- Thrombolytic therapy: current status (2). (1988) (16)
- The physiologic basis for therapy of classic hemophilia (factor 8 deficiency) and related disorders. Combined clinical staff conference at the National Institutes of Health. (1967) (16)
- A Simple Technique for the Measurement of Plasma Heparin Concentration during Anticoagulant Therapy (1970) (16)
- The effect of carbohydrate depletion on procoagulant activity and in vivo survival of highly purified human factor VIII. (1984) (16)
- What does the "Dimertest" test? (1990) (15)
- Electron microscopic studies of plasmic degradation products of fibrinogen. Implications for the disulfide structure of fibrinogen. (1975) (15)
- Terminology for Macromolecular Plasmic Derivatives of Crosslinked Fibrin (1987) (15)
- The Functional Defects of Hereditary Dysfibrinogens (1976) (15)
- Leukocyte filtration lesion impairs functional coagulation in banked whole blood (2017) (15)
- Tissue factor mRNA expression in the endothelium of an intact umbilical vein. (1996) (15)
- Carboxyl-terminal amino acid sequences of two variant forms of the gamma chain of human plasma fibrinogen. (1988) (15)
- Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products. (1986) (14)
- Magnesium sulfate neither potentiates nor inhibits tissue plasminogen activator‐induced thrombolysis (2006) (13)
- The structure of the fibrinogen degradation products. (1974) (13)
- Are we using fibrinolytic agents often enough? (1980) (13)
- The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests. (1989) (13)
- Hemostasis and Thrombosis: Basic (1995) (12)
- Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients (1992) (12)
- Post-transcriptional regulation of endothelial cell plasminogen activator inhibitor-1 expression during R. rickettsii infection. (2000) (12)
- Comparison of Plasmin With Recombinant Tissue-Type Plasminogen Activator in Lysis of Cerebral Thromboemboli Retrieved From Patients With Acute Ischemic Stroke (2011) (12)
- Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits. (1991) (11)
- History of Hypertension and Enhanced Thrombogenic Activity in Postinfarction Patients (2003) (11)
- Comparison of thrombolytic agents: selected hematologic, vascular and clinical events. (1989) (11)
- Comprar Colman's Hemostasis and Thrombosis, 6/e Basic Principles and Clinical Practice | Victor J. Marder | 9781608319060 | Lippincott Williams & Wilkins (2012) (11)
- Automated Latex Agglutination and ELISA Testing Yield Equivalent D-Dimer Results in Patients with Recent Myocardial Infarction (1999) (11)
- Safety evaluation of a recombinant plasmin derivative lacking kringles 2–5 and rt-PA in a rat model of transient ischemic stroke (2012) (10)
- Thrombolytic Therapy: Overview of Results in Major Vascular Occlusions (1995) (10)
- Determination of Human Fibrinopeptide A by Radioimmunoassay in Purified Systems and in the Blood (1975) (10)
- ISOANTIBODIES AGAINST PLATELETS AND LEUKOCYTES. (1964) (10)
- Bleeding complications of thrombolytic treatment. (1990) (9)
- An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. (1984) (9)
- Molecular bad actors and thrombosis. (1984) (9)
- Antithrombin III/low-dose heparin in the prevention of deep-vein thrombosis after total knee arthroplasty. A preliminary report. (1989) (9)
- Foundation and sites of action of antithrombotic agents. (2004) (9)
- Plasma urokinase levels measured by chromogenic assay after infusions of tissue culture or urinary source material. (1980) (9)
- The Half-Life of Plasmic Degradation Products of Human Fibrinogen in Rabbits (1977) (8)
- Prolonged remission after life‐threatening gastrointestinal hemorrhage from coexistent angiodysplasia and acquired bleeding diathesis (1988) (8)
- Degradation Pathway of Fibrinogen by Plasmin (1977) (8)
- Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy. (1992) (8)
- Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding (2003) (8)
- Temperature-sensitive steps in the secretory pathway for von Willebrand factor in endothelial cells. (1989) (8)
- Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia (2015) (8)
- The pattern of errors in delayed recall of serial learning after interpolation. (1957) (8)
- Plasmic degradation of fibrinogen Paris I. (1976) (8)
- Thrombosis, fibrinolysis, and thrombolytic therapy: a perspective. (1991) (7)
- Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2–5 (2010) (7)
- Opinions and research priorities. (2005) (7)
- Cloning of Guinea Pig Tissue Factor cDNA: Comparison of Primary Structure among Six Mammalian Species (2000) (7)
- Variations of heparin therapy for thromboembolic disease. (1974) (6)
- Single‐nucleotide variations defining previously unreported ADAMTS13 haplotypes are associated with differential expression and activity of the VWF‐cleaving protease in a Salvadoran congenital thrombotic thrombocytopenic purpura family (2014) (6)
- COMPARISON OF IMMUNOLOGIC AND IDIOPATHIC THROMBOCYTOPENIA. (1964) (6)
- Inhibiting the inhibitor. (1992) (6)
- Pharmacology of thrombolytic agents. Implications for therapy of coronary artery thrombosis. (1983) (6)
- Comparison of the in vivo survival of human factor VIII with and without von Willebrand factor in the hemophilic dog. (1986) (6)
- Platelet coagulant activities and venous thrombosis after hip surgery. (1974) (6)
- Women's issues in thrombosis and hemostasis (2002) (5)
- Structural Abnormality in the Gamma Polypeptide Chain of Paris I Fibrinogen (1975) (5)
- Comparison of a chromogenic prothrombin time with clotting prothrombin time in the assessment of clinical coagulation deficiencies. (1985) (5)
- Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No (2005) (5)
- Sedimentation analysis of von Willebrand and factor VIIIC protein using partition cells in the analytical ultracentrifuge. (1984) (5)
- More on the GUSTO Trial (1994) (5)
- HETEROGENEITY OF NORMAL HUMAN FIBRINOGEN DUE TO TWO HIGH MOLECULAR WEIGHT VARIANT γ CHAINS (1983) (5)
- Evaluation of a New Anti-Fibrinogen-Coated Latex Particle Agglutination Test in the Measurement of Serum Fibrin Degradation Products (1977) (5)
- Monitoring of Therapy for Deep Vein Thrombosis Using Magnetic Resonance Imaging (1989) (5)
- Interference of thrombin in immunological assays for hirudin specific antibodies. (2012) (4)
- Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation. (1986) (4)
- Successful Thrombolytic Therapy in Two Patients With Renal Vein Thrombosis (1985) (4)
- Electron Microscopic Studies of the Factor VIII-Von Willebrand Factor Protein (1977) (4)
- Tolerance and complications in a multicenter trial of intravenous apsac and intracoronary streptokinase in acute myocardial infarction (1990) (4)
- Quantitative assessment of after thrombolysis in acute myocardial infarction: Results of a randomized study of anistreplase and streptokinase (1990) (3)
- Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study. (2017) (3)
- Distinctive Neoantigenic Marker Associated with a Plasmic Derivative (Fragment D-D) of Cross Linked Human Fibrin (1977) (3)
- The role of cocaine in the etiology of Buerger disease is questionable. (2001) (3)
- Chapter 28 – Thrombolytic Therapy* (2007) (3)
- Disorders that resemble lymphomas (1997) (3)
- Dose-Ranging Studies of Anisoylated Plasminogen Streptokinase Activator Complex (2012) (3)
- Heterogeneity of normal human fibrinogen due to two high molecular weight variant gamma chains. (1983) (3)
- The interaction of dietary supplements with antithrombotic agents: scope of the problem. (2005) (3)
- Fibrinogen Concentration and Coronary Artery Reperfusion after Intravenous Anisoylated Plasminogen Streptokinase Activator Complex or Intracoronary Streptokinase Therapy (2012) (3)
- 28 – Thrombolytic Therapy (2013) (2)
- High Molecular Weight Derivatives of Human Fibrinogen (2003) (2)
- Isoimmune neonatal purpura (1963) (2)
- On the significance of marginally low von Willebrand factor (2008) (2)
- Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system. (2014) (2)
- Fibrinolytic treatment of acute or subacute arterial thrombosis. (1976) (2)
- Short-Term Variation of Inflammatory Markers in Chronic Obstructive Pulmonary Disease (COPD) Patients (2008) (2)
- Glomerular hemophagocytic macrophages in a patient with proteinuria and clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH) (2011) (2)
- Comparison of in Vivo Biochemical Effects of Human Urokinase Prepared from Urinary and Tissue Culture Sources (1977) (2)
- Unusual anemias (1997) (2)
- PS124. Plasmin (Human) TAL-05-00018 Demonstrates a Good Safety Profile in Patients with Acute Peripheral Arterial Occlusion (2011) (2)
- THE PRIORITY TRIAL: PLASMIN REVASCULARIZATION OF ACUTE LOWER EXTREMITY NATIVE ARTERY OR BYPASS GRAFT OCCLUSION-PHASE I/II PROTOCOL DESIGN (2007) (1)
- [Action of the products of fibrinogen degradation on plalet function]. (1967) (1)
- The Association Of Thrombin With Fibrin And Its Solubilization During Plasmic Digestion (1981) (1)
- Determination of Plasma Urokinase Levels by Chromogenic Assay Levels: Comparison of Levels Attained During Infusion of Tissue Culture and Urinary Source Urokinase Preparations (1979) (1)
- C0131 Comparison of the efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation using network meta-analysis (2012) (1)
- A PHASE I TRIAL OF LOCALLY-DELIVERED HUMAN PLASMIN TO EVALUATE SAFETY AND THROMBOLYTIC EFFICACY IN PATIENTS WITH HEMODIALYSIS GRAFT OCCLUSION (HGO) (2007) (1)
- Structural considerations of plasmic degradation of fibrinogen. (1974) (1)
- Metabolism and Distribution of Fibrinogen 11. FIBRINOGEN TURNOVER IN POLYCYTHAEMIA, THROMBOCYTOSIS, HAEMOPHILIA A, CONGENITAL AFIBRINOGENAEMIA AND DURING STREPTOKINASE THERAPY (1972) (1)
- Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study (2013) (1)
- Orally Active Heparin (2002) (1)
- Physiological Balance of Haemostasis and Bleeding (2012) (1)
- How Have Trials of Thrombolytics Influenced Clinical Management of Patients with Acute Myocardial Infarction (1997) (1)
- Comparison of Plasmin with rt-PA in Lysis of Cerebral Thromboemboli Retrieved from Patients with Acute Ischemic Stroke (2011) (1)
- Proposed symbols for factor VIII and von Willebrand factor. (1986) (1)
- The Physiologic Basis for Therapy of Classic Hemophilia (Factor VIII Deficiency) and Related Disorders (2020) (1)
- Conference summary and recommendations for research. (2005) (1)
- Thromboembolism: New Insights and Future Prospects: 7th International Symposium on Thromboembolic Diseases, Palma de Mallorca, June 2000: Proceedings (2001) (0)
- The rt-PA versus streptokinase controversy--III. (1992) (0)
- [Pharmacology and practical therapy. Physiopathology and therapy of disseminated intravascular coagulation]. (1973) (0)
- Buerger Disease or Arsenic Intoxication?—Reply (2001) (0)
- The association between inflammatory markers and thrombogenic factors in postinfarction patients (2002) (0)
- Hydrodynamic Studies Of Von Willebrand Protein And Factor VIIIc Using The Partition Cells In The Analytical Ultracentrifuge (1981) (0)
- Pharmacology of thrombolytic agents (2005) (0)
- Multicenter Keperfusion Trial of ~ntr~ve~~~s Anisoy Streptokinase Activator Complex (APSAC) in Acute Infarction: Controlled Comparison With Intracoronary Stre (2016) (0)
- Response to Letter by Culp and Culp (2008) (0)
- Low molecular weight heparins and antithrombotic therapy (1997) (0)
- AMBIENT AIR POLLUTION AND SOLUBLE CD40L IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) (2005) (0)
- Radioimmunoassays of human fibrinopeptides A and B. (1978) (0)
- Structural Studies on the Functional Heterogeneity of (2016) (0)
- Identification of Crosslinked Fibrin Degradation Products in Plasma of Patients During Fibrinolytic Therapy Using a Heat Extraction/SDS-Polyacrylamide Gradient Gel Electrophoretic Technique (1979) (0)
- The use of fraction I for oral surgical procedures in patients with classic hemophilia: report of seven cases. (1966) (0)
- Degradation of bovine factor 8 by plasmin and trypsin. (1974) (0)
- Maximized Hemostasis (2002) (0)
- VTE Prophylaxis with Desirudin in Patients with Thrombocytopenia: Insights From the DESIRABLE Trial, (2011) (0)
- Experience of the First 6 Congresses of the International Society on Thrombosis and Haemostasis (1978) (0)
- Low-molecular-weight heparins-new frontiers in antithrombotic therapy, San Diego, Calif., December 5, 1997 (1997) (0)
- Discussion: Section 4 (2012) (0)
- Electron Microscopic Studies of Fibrinogen Degradation Products (1975) (0)
- Inherited bleeding disorders in women (2002) (0)
- LOW-MOLECULAR-WEIGHT HEPARIN AND VENOUS THROMBOSIS. REPLY (1991) (0)
- MYOCARDIAL INFARCTION Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction (0)
- Chapter 19 – Transplantation for Hematological Disorders (2015) (0)
- Thrombolytic Agents: Balancing Cost, Efficacy, and Side Effects (1990) (0)
- 17 – Liver Transplantation for Hematological Disorders (2005) (0)
- Thromboembolic complications of hip fractures. (1974) (0)
- Substitute indoles and their use as an integrine antagonists. (2002) (0)
- Preclinical Studies for Sickle Cell Disease Gene Therapy Using Bone Marrow CD34+ Cells Modified with a βAS3-Globin Lentiviral Vector (2011) (0)
- Sol Sherry, M. D. (1916–1993) (1993) (0)
- Conclusion (2001) (0)
- Role of Soluble Crosslinked Fibrin Polymers (2005) (0)
- #661 Apoptotic gene protein expression in low grade versus high grade pediatric gliomas (1998) (0)
- Infections affecting blood cell morphology (1998) (0)
- receiving antithrombotic prophylaxis with fondaparinux or enoxaparin Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients (2013) (0)
- Single-Nucleotide Variations Defining Previously Unreported ADAMTS13 Haplotypes Are Associated With Differential Expression and Activity Of The VWF-Cleaving Protease In a Salvadoran Congenital Thrombotic Thrombocytopenic Purpura Family (2013) (0)
- Low molecular weight heparins and antithrombotic therapy: results of an audience-interactive symposium. (1997) (0)
- Low-molecular-weight heparin and venous thrombosis. (1991) (0)
- Comparison of intravenous APSAC (anisoylated plasminogen streptokinase activator complex) and intracoronary streptokinase in acute myocardial infarction: Interim results of the United States randomized study (1987) (0)
- THROMBOLYSIS Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction (2005) (0)
- Technical and practical limitations of whole slide digital imaging in the analysis of intracranial thrombectomies (2008) (0)
- Chapter 2B Nonenzymatic cofactors: factor VIII (1986) (0)
- Pathophysiology and therapy of disseminated intravascular coagulation. (1971) (0)
- Fibrinogen and its derivatives, hereditary and acquired abnormalities. (1974) (0)
- Fibrinoloytic parameters in patients with acute myocardial infarction treated with intravenous APSAC or intracoronary streptokinase (1987) (0)
- A Unique Recombinant Plasmin Molecule Lacking Kringles 2-5 Possesses Equivalent Hemostatic Safety as Full-Length Human Plasmin. (2008) (0)
- Potentiation of wheat germ agglutinin aggregation of platelets by von Willebrand protein and by a 116,000 molecular weight tryptic fragment. (1983) (0)
- Streptokinase and Anisoylated Lys-Plasminogen Streptokinase Activator Complex (2001) (0)
- Chairman’s Comments (2001) (0)
- ID: 357 Plasmin: a Direct Thrombolytic Agent (2006) (0)
- Panel Discussion (2012) (0)
- Supplemental Alpha-2-Antiplasmin Prevents Plasmin-Induced Hemorrhage. (2004) (0)
- Medicine and Books (1983) (0)
- The NH2-terminal amino acids of the fibrinogen degradation products. Implications for fibrinogen structure. (1973) (0)
- Cocaine and Buerger Disease (2017) (0)
- [APPLICATION OF IMMUNOCHEMICAL TECHNICS TO THE STUDY OF FIBRINOGEN AND ITS PRODUCTS OF DEGRADATION BY PLASMIN]. (1965) (0)
- Proceedings: Electron microscopic studies of fibrinogen degradation products. (1975) (0)
- Low-Molecular-Weight Heparins - New Frontiers in Antithrombotic Therapy: Super Friday Symposium, San Diego, Calif., December 1997 (1997) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Victor J. Marder?
Victor J. Marder is affiliated with the following schools:
